

1 **Plasma cell maintenance and antibody secretion are under the control of Sec22b-mediated**  
2 **regulation of organelle dynamics**

3 Amélie Bonaud<sup>1,2,3</sup>, Laetitia Gargowitsch<sup>4</sup>, Simon M. Gilbert<sup>5</sup>, Elanchezhian Rajan<sup>6</sup>, Pablo Canales  
4 Herrerias<sup>7</sup>, Daniel Stockholm<sup>8-9</sup>, Nabila F. Rahman<sup>10</sup>, Mark O. Collins<sup>6</sup>, Danika L. Hill<sup>11,12</sup>, Andres  
5 Alloatti<sup>13,14</sup>, Nagham Alouche<sup>4</sup>, Stéphanie Balor<sup>15</sup>, Vanessa Soldan<sup>15</sup>, Daniel Gillet<sup>16</sup>, Julien Barbier<sup>16</sup>,  
6 Françoise Bachelier<sup>4</sup>, Kenneth G.C. Smith<sup>5,17</sup>, Pierre Bruhns<sup>7</sup>, Sebastian Amigorena<sup>13</sup>, Karl  
7 Balabanian<sup>1,2,3</sup>, Michelle A. Linterman<sup>11</sup>, Andrew A. Peden<sup>6</sup> and Marion Espéli<sup>1,2,3\*</sup>

8  
9 *1- Université de Paris, Institut de Recherche Saint-Louis, INSERM U1160, F-75010 Paris, France,*  
10 *2- CNRS, GDR3697 “Microenvironment of tumor niches”, Micronit, France,*  
11 *3- OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris,*  
12 *France*  
13 *4- Université Paris-Saclay, INSERM, Inflammation, Microbiome and Immunosurveillance, Clamart,*  
14 *France.*  
15 *5- Department of Medicine, University of Cambridge, Cambridge Biomedical Campus, Addenbrooke’s*  
16 *Hospital, Cambridge, UK.*  
17 *6- School of Bioscience, University of Sheffield, Western Bank, Sheffield, S102TN, UK*  
18 *7- Institut Pasteur, Université de Paris, Unit of Antibodies in Therapy and Pathology, Inserm UMR1222,*  
19 *F-75015 Paris*  
20 *8- PSL Research University, EPHE, Paris, France*  
21 *9- Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012, Paris, France*  
22 *10- Dementia Research Institute, University of Cardiff, Hadyn Ellis Building, Maindy Road, Cardiff,*  
23 *CF24 4HQ*  
24 *11- Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus,*  
25 *Cambridge CB22 3AT, UK*  
26 *12- Department of Immunology and Pathology, Monash University, Melbourne, Victoria, 3004,*  
27 *Australia*  
28 *13- PSL Research University, Institut Curie Research Center, INSERM U932, Paris, France*  
29 *14- Facultad de Ciencias Médicas, Instituto de Inmunología Clínica y Experimental de Rosario*  
30 *(IDICER)-CONICET/Universidad Nacional de Rosario, Rosario, Argentina.*  
31 *15- METi, Centre de Biologie Intégrative, Université de Toulouse, CNRS, UPS, 31062, Toulouse,*  
32 *France*  
33 *16- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé*  
34 *(DMTS), SIMoS, 91191 Gif-sur-Yvette, France*  
35 *17- Jeffrey Cheah Biomedical Centre Cambridge Biomedical, Cambridge Institute of Therapeutic*  
36 *Immunology & Infectious Disease, University of Cambridge, Cambridge, United Kingdom*

37  
38  
39 \* Corresponding author: [marion.espeli@inserm.fr](mailto:marion.espeli@inserm.fr)

40

41 **Short title: Sec22b controls plasma cell biology**

42 **Keywords:** Plasma cell – antibody – SNARE - Endoplasmic reticulum – Mitochondria.

43

44 **Abstract**

45 Despite the essential role of plasma cells in health and disease, the cellular mechanisms controlling their  
46 survival and secretory capacity are still poorly understood. Here, we identified the SNARE Sec22b as a  
47 unique and critical regulator of plasma cell maintenance and function. In absence of Sec22b, plasma  
48 cells were barely detectable and serum antibody titres were dramatically reduced. Accordingly, *Sec22b*  
49 deficient mice fail to mount a protective immune response. At the mechanistic level, we demonstrated  
50 that Sec22b is indispensable for efficient antibody secretion but also for plasma cell fitness through the  
51 regulation of the morphology of the endoplasmic reticulum and mitochondria. Altogether, our results  
52 unveil a critical role for Sec22b-mediated regulation of plasma cell biology through the control of  
53 organelle dynamics.

54

55

56

57

58 **Introduction:**

59 Plasma cells (PCs) are the cellular source of humoral immunity via the long-term secretion of large  
60 quantities of antibodies that provide protection against reinfection. These cells can also contribute to  
61 diseases including plasmacytomas as well as antibody-mediated autoimmune and inflammatory  
62 pathologies. However, the therapeutic arsenal to target PCs is still very limited. Despite the essential  
63 role of PCs in health and disease, the cellular mechanisms controlling their secretory function and their  
64 survival are poorly understood. Closing this knowledge gap is thus of paramount importance for  
65 designing new approaches to target this cell type.

66 During the transition from B cell to PC, the cell is reprogrammed to produce and secrete around  $10^2$ - $10^3$   
67 antibodies per second<sup>1</sup>. To accommodate this large protein load, PCs expand their endoplasmic  
68 reticulum (ER) and adapt to tolerate the extra stress induced via upregulation of the Ire1 $\alpha$ /Xbp1 branch  
69 of the unfolded protein response (UPR)<sup>2-4</sup>. Early works from the 70s report that antibody secretion  
70 happens via the conventional constitutive exocytosis pathway meaning that they are not pre-stocked in  
71 granules but secreted as they are produced through the Golgi apparatus where they are glycosylated<sup>5-7</sup>.  
72 Antibody transport from the expanded ER to the Golgi apparatus is thus the key bottleneck in this  
73 process, however, the molecular mechanisms at play are still unknown<sup>8</sup>.

74 Members of the Soluble N-ethylmaleimide-sensitive factor Attachment Protein Receptor (SNARE)  
75 family are essential for the intracellular transport and fusion of protein cargoes between organelles. They  
76 are involved in both regulated and constitutive exocytosis and form a large family composed of different  
77 subtypes (Qa-, Qb-, Qc- and R-SNAREs)<sup>9</sup>. Distinct sets of SNAREs are expressed on the different  
78 organelles and can also be cell type specific<sup>10</sup>. On top of vesicular transport, SNAREs can have other  
79 non-canonical functions, some of which could be highly relevant for PC biology, including ER  
80 branching, regulation of autophagosome maturation as well as plasma membrane expansion<sup>11-16</sup>.

81 In this work we explore the role of SNARE proteins required for ER to Golgi transport, and in particular  
82 of Sec22b, in antibody secretion and PC biology. In absence of Sec22b PCs are dramatically reduced.  
83 The transport of antibodies from the ER to the Golgi is impacted leading to a strong decrease in antibody  
84 secretion and an incapacity to generate a protective humoral response. This defect in antibody  
85 production and PC survival is accompanied by deregulation of the UPR and a defective ER morphology.

86 In addition, we observed that in absence of Sec22b the mitochondrial network is hyperfused suggesting  
87 a key role for this protein in the regulation of ER-mediated mitochondrial fission. Altogether our results  
88 establish Sec22b as a critical regulator of PC biology through the control of conventional constitutive  
89 secretion but also through the regulation of organelle morphology and dynamics.

90

91


92

93 **Results:**

94 *The Syntaxin-5/Sec22b SNARE complex is overexpressed in plasma cells:*

95 To identify new molecular actors that contribute to antibody secretion and PC fitness we analysed the  
96 expression of molecules involved in ER to Golgi transport by mining a proteogenomic database using  
97 the Plasmacytomics interface (<https://plasmacytomics.shinyapps.io/home/> ; manuscript in preparation).  
98 To determine the validity of the platform we first confirmed that the expression of well-known factors  
99 of B cell and PC differentiation behaved as one would predict. As expected, the B cell transcription  
100 factor Pax5 was significantly downregulated in PCs compared to B cells while genes encoding the  
101 transcription factor Xbp1 and the PC marker CD138 (*Sdc1*) were significantly upregulated in PCs  
102 (Figure 1A). Molecules involved in ER to Golgi trafficking, including SNAREs (Syntaxin 5, Sec22B  
103 and Ykt6), a tethering factor (USO1/p115) and the Sec1/Munc-18 protein (SCFD1/Sly1), were  
104 upregulated at the transcriptional level in PCs compared to B cells (Figure 1A). In support of the  
105 transcriptomic data, we also observed a significant increase in the levels of many of these proteins by  
106 mass-spectrometry (Figure 1B and Supplementary Figure 1) and immunoblotting (Figure 1C).  
107 Datamining of human RNAseq datasets using the plasmacytomics platform also showed significantly  
108 increased expression of *SEC22B* and *STX5A* in human PCs compared to B cells (Figure 1D) suggesting  
109 that these changes are conserved across species.

Figure 1



**Figure 1: The Syntaxin-5-Sec22b SNARE complex is overexpressed in plasma cells:**

A) The PlasmacytOMICs interface (manuscript under preparation) was used to perform a meta-analysis of gene expression changes between murine Naive B cells and a range of antibody secreting cell types (mSpIPC.Array = microarray / mouse splenic PCs; mBMPC.Array = microarray / mouse BM PCs; mPB.rSeq = RNAseq / mouse plasmablasts generated *in vitro*; mSpIPC.rSeq = RNAseq / mouse splenic PCs; mBMPC.rSeq = RNAseq / mouse BM PCs) for the indicated genes. The  $\text{Log}_2$  Fold change between naïve B cells and the indicated cell subset is shown for each gene. Error bars show SEM. \* - indicates False Discovery Adjusted p-value < 0.05. B) Changes in protein abundance between murine Naive B cells and CD138 enriched PCs generated *in vitro* were measured using label free LC-MS/MS analysis and plotted using the PlasmacytOMICs interface. The  $\text{Log}_2$  Fold change between naïve B cells and the indicated cell subset is shown for each protein. Error bars show SEM. \* - indicates False Discovery Adjusted p-value < 0.05. We were unable to consistently measure sufficient peptides for quantification of CD138 in the PC samples possibly due to its high level of glycosylation. The fold change shown for XBP1 is an underestimate, as the ratio plotted is calculated using an imputed value for the B-cell samples as the protein was not detected in these samples (see Supplementary Figure 1). C) Representative immunoblots for Xbp1, IgM, CD138, Scfd1, Uso1, Stx5, Ykt6, Sec22b and b-actin (top to bottom respectively) from samples prepared from splenic B cells (left panel) or CD138 enriched *in vitro* differentiated PCs (right panel). The band shown for CD138 is the non-glycosylated form of the protein. For Stx5 the two bands correspond to the short and the long isoforms of the protein. The fold change between B cells and PCs normalized to b-actin is indicated on the right for each protein. D) Changes in gene expression between human Naive B cells and selection of human antibody secreting cell types (hPB.rSeq = RNAseq / human blood PC; hBMPC.rSeq = RNAseq / human BM PC) were calculated for the indicated genes using the PlasmacytOMICs platform. The  $\text{Log}_2$  Fold change between naïve B cells and the indicated cell subset is shown for each gene. Error bars show SEM. \* - indicates False Discovery Adjusted p-value < 0.05.

110

111 Previous works has shown that the Golgi-localised SNARE, Stx5 forms a complex with the ER-localised

112 Sec22b to allow fusion of transport vesicles between these two organelles<sup>10,17,18</sup>. To test the functional

113 relevance of Stx5 expression in PC biology, we developed a cell culture and differentiation assay using

114 control shRNA or an shRNA specific for Stx5 together with GFP reporter expression (Supplementary

115 Figure 2A-D). We confirmed on sorted cells that Stx5 knock-down (KD) GFP<sup>+</sup> PCs expressed less Stx5

116 at the transcriptional level than GFP<sup>+</sup> PCs (Supplementary Figure 2B). From two days after LPS-induced  
117 differentiation, PCs were generated from B cells and their frequency was roughly similar between  
118 control and Stx5 KD samples (Supplementary Figure 2C-D left panel). However, from day 4 onwards,  
119 the frequency of total PCs in the Stx5 KD samples progressively diminished to half of the frequency  
120 observed at day 2 while it was constant in the control samples during the same period (Supplementary  
121 Figure 2D left panel). Strikingly, the frequency of GFP<sup>+</sup> PCs was rapidly decreasing in the Stx5 KD  
122 samples while it remains constant throughout the experiment in control samples, suggesting that Stx5  
123 KD confers an intrinsic disadvantage to PCs (Supplementary Figure 2D, central panel). The frequency  
124 of GFP<sup>+</sup> B cells was not modified by Stx5 KD (Supplementary Figure 2D, right panel), confirming the  
125 specific requirement of Stx5 expression for PC persistence *in vitro*. We next took advantage of a small  
126 molecule, Retro-2, reported to block Stx5 function by mislocalizing it and blocking its recycling<sup>19,20</sup> to  
127 assess the impact of Stx5 on antibody secretion. When *in vitro* differentiated WT PCs were cultured for  
128 5 hours in presence of increasing doses of Retro-2 we observed a dose dependent reduction of antibody  
129 secretion (Supplementary Figure 2E). Injection of a single dose of Retro-2 intraperitoneally to WT mice  
130 led to a significant reduction of the antibodies secreted by BM PCs after 3 days without reduction of the  
131 number of PCs in this organ (Supplementary Figure 2F), supporting a role for Stx5 in antibody secretion  
132 on top of PC survival. Altogether our data suggest that the machinery required for ER to Golgi transport  
133 including Stx5/Sec22b is upregulated during PC differentiation and that disruption of Stx5 leads to  
134 defects in PC viability and function.


135

136 *Dramatic loss of plasma cells and circulating antibodies in absence of Sec22b:*

137 Taking in consideration the effect of Stx5 on PC maintenance and antibody secretion, we next explored  
138 the implication of its partner Sec22b. We crossed a Sec22b floxed mouse model<sup>11</sup> with the mb1-cre  
139 strain to generate a mouse model lacking Sec22b expression specifically in the B cell lineage  
140 (Sec22b<sup>flox/flox</sup> x mb1-cre, hereafter referred to as Sec22b<sup>B-KO</sup>) (Supplementary Figure 3A-B). In absence  
141 of Sec22b, B cell development was roughly normal with only a mild reduction of the number of BM  
142 mature B cells and splenic follicular B cells compared to WT mice, whereas BM B cell precursors,  
143 splenic immature, marginal zone and CD93<sup>-</sup>/CD21<sup>-</sup>/CD23<sup>-</sup> B cells were unaffected (Supplementary

144 Figure 3C-D). At steady state  $Sec22b^{B-KO}$  mice had almost no circulating antibody for all the isotypes  
 145 tested (Figure 2A). Igk representing around 90% of secreted antibodies in the mouse were reduced over  
 146 40 times. IgG1 titres were 55 times lower in absence of Sec22b. IgM, IgA and IgG3 were 40, 30 and 20  
 147 times lower in absence of Sec22b, respectively (Figure 2A).

**Figure 2**



148




149 This was associated with a ten-fold reduction of the frequency and absolute number of PCs in the spleen  
150 and the BM with the mature CD19<sup>+</sup>B220<sup>-</sup> PCs being the most affected (Figure 2B and C). Accordingly,  
151 we observed that the remaining splenic PCs in Sec22b<sup>B-KO</sup> mice display a less mature profile than their  
152 WT counterparts with reduced expression of the PC markers *Cd93* and *Tnfrsf13b* and of the PC master  
153 regulators *Prdm1*, *Xbp1* and *Irf4*. In contrast enhanced expression of the B cell master regulators *Pax5*  
154 and *Bach2* were detected at the transcriptional level in Sec22b<sup>B-KO</sup> PCs compared to WT (Figure 2D).  
155 Thus, our results demonstrate that Sec22b plays a critical and non-redundant role in PC maintenance  
156 and in the control of antibody circulating titres in vivo.

157

158 *Sec22b is indispensable for the generation of a protective humoral immune response:*

159 Considering the importance of PCs and circulating antibodies for the humoral immune response, we  
160 next assessed the impact of *Sec22b* deficiency on these processes. Following T-dependent immunization  
161 with sheep red blood cells (SRBC) (Figure 3A-C), the frequency and number of PCs in the spleen  
162 remained extremely low in Sec22b<sup>B-KO</sup> mice, being reduced over 100 times compared to controls (Figure  
163 3B). A similar observation was made for antibody titres after SRBC immunization (Figure 3C). We also  
164 investigated antigen specific humoral immune response by immunizing with the T-dependent antigen  
165 NP-KLH in alum and boosting with NP-KLH only (Figure 3D). Seven days after the boost the frequency  
166 and numbers of splenic and BM PCs were again significantly reduced in absence of Sec22b (Figure 3E).  
167 Moreover, we barely detected NP-specific IgM and IgG1 antibodies in the serum of Sec22b<sup>B-KO</sup> mice  
168 throughout the immunization while a potent antibody immune response with the expected kinetics was  
169 observed in control animals (Figure 3F). We next infected WT and *Sec22b* deficient mice with influenza  
170 A virus (Figure 3G) and observed a profound defect in the frequency and number of PCs in the draining  
171 mediastinal lymph nodes (Figure 3H). Flu-specific antibodies were undetectable in the serum of *Sec22b*  
172 deficient mice (Figure 3I). These defects were associated with exacerbated weight loss in Sec22b<sup>B-KO</sup>  
173 mice compared to their WT littermates suggesting a poorer control of the infection in absence of Sec22b  
174 (Figure 3J). Altogether, these results establish that Sec22b is required for the establishment of a potent  
175 and efficient humoral immune response after both vaccination and infection.

176




**Figure 3: Sec22b is indispensable for the generation of a protective humoral immune response:**

A) Schematic representation of the SRBC immunisation protocol for Sec22b<sup>WT</sup> and Sec22b<sup>B-KO</sup> mice. B) Representative dot plots (top), frequency (bottom left) and absolute number (bottom right) of splenic PCs (CD138<sup>+</sup>B220<sup>+</sup>) determined by flow cytometry 7 days after SRBC immunization. C) ELISA quantification of IgM (top) and IgG1 (bottom) serum titres 7 days after SRBC immunized. A-C one representative experiment of 2 is shown. D) Schematic representation of the NP-KLH immunization/ boost protocol. Sec22b<sup>WT</sup> or Sec22b<sup>B-KO</sup> mice were immunized, rechallenged 28 days later and analysed 7 days later. Sera were collected at days 7-, 14-, 21- and 7-days post boost. E) Frequency (left) and absolute number (right) of splenic PCs (CD138<sup>+</sup>B220<sup>+</sup>) (top) and bone marrow (BM) PCs (CD138<sup>+</sup>B220<sup>+</sup>) (bottom) determined by flow cytometry 7 days post boost with NP-KLH (n=9 mice from 2 pooled independent experiments). F) ELISA quantification of NP-IgM (top) and NP-IgG1 (bottom) serum titres at days 7-, 14-, 21- post primary immunization and 7-days post boost (n=5 mice. One experiment representative of 2 is shown). G) Schematic representation of the Flu infection protocol for Sec22b<sup>WT</sup> and Sec22b<sup>B-KO</sup> mice. Mice were analysed 14 days after infection with influenza A virus. H) Frequency (left) and absolute number (right) of mediastinal PCs (CD138<sup>+</sup>B220<sup>+</sup>) determined by flow cytometry 14 days after infection with influenza A virus. I) Quantification of HAI titres 14 days post flu infection. J) Weight change of Sec22b<sup>WT</sup> or Sec22b<sup>B-KO</sup> mice over 12 days after flu infection. (H-I; n=5, one representative experiment of 2 is shown, J; n=15 from 2 pooled experiments) For flow cytometry experiment cells were first gated on their size and structure, then their viability. Dead cells and doublets were excluded. The p-values were determined with the two-tailed Mann-Whitney non-parametric test \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001; \*\*\*\*p < 0.0001 or with the 2way ANOVA with Sidak correction for multiple comparisons (££ p < 0.01, £££ p < 0.001).

178 *Sec22b* is necessary for plasma cell maintenance and secretory function but not for the initiation of  
 179 differentiation:

180 To unravel at which step of PC differentiation *Sec22b* is required, we performed *in vitro* differentiation  
 181 assays of splenic B cells. In control cultures PC frequency doubles between day 2 and day 4, whereas it  
 182 remains constant between these two time points in *Sec22b*<sup>B-KO</sup> cultures (Figure 4A-B).

**Figure 4**



**Figure 4: *Sec22b* is necessary for plasma cell maintenance and function**

A-B) Representative dot plots (A) and quantification (B) of PCs (CD138<sup>hi</sup>B220<sup>lo</sup>) generated *in vitro* from *Sec22b*<sup>WT</sup> and *Sec22b*<sup>B-KO</sup> splenocytes after 2 or 4 days of stimulation with LPS. Cells were gated on their size and structure, on their viability and doublets were excluded. C) Frequency of Caspase 3<sup>+</sup> PCs at day 2 and 4 post LPS stimulation determined by flow cytometry. D) Flow cytometry analysis of the cell cycle phases based on DAPI and Ki-67 staining in *in vitro* generated *Sec22b*<sup>WT</sup> and *Sec22b*<sup>B-KO</sup> PCs at day 2 (left) and day 4 (right) post LPS stimulation. E) ELISA quantification of total IgM secreted in the culture supernatant of PCs generated from *Sec22b*<sup>WT</sup> and *Sec22b*<sup>B-KO</sup> splenocytes after 2 or 4 days of LPS stimulation. F) Quantification of the IgM secretion rate from *in vitro* generated PCs from *Sec22b*<sup>WT</sup> and *Sec22b*<sup>B-KO</sup> splenocytes after 2 or 4 days of LPS stimulation analysed by DropMap. Each point represent one cell. (A-B) n=12-16 mice from at least 3 pooled independent experiments. (C-D) n=4 of 1 representative experiment out of 2. (E) n=8 in 3 independent experiments; (F) n=2 in 2 independent experiments. The p-values were determined with the two-tailed Mann-Whitney non-parametric test \**p* < 0.05; \*\**p* < 0.01; \*\*\**p* < 0.001, “ns” = non-significant *p*-value.

183

184 This was associated with an enhanced apoptosis of *in vitro* derived PCs lacking Sec22b as detected by  
185 the frequency of active Caspase3<sup>+</sup> cells (Figure 4C). In addition, cell cycle was impaired in Sec22b<sup>B-KO</sup>  
186 PCs generated *in vitro* with a progressive exit from the cell cycle particularly clear at day 4 (Figure 4D).  
187 These results indicate that Sec22b is not required for the initiation of PC differentiation but is important  
188 for the maintenance of this cell subset. In line with the reduced frequency of PCs generated we observed  
189 a decreased amount of total IgM in the culture supernatant in absence of Sec22b (Figure 4E). To assess  
190 more precisely the impact of *Sec22b* deficiency on antibody secretion we took advantage of a droplet  
191 microfluidic-based technique to assess the secretion rate at the single cell level <sup>1</sup>. Between 6000 and  
192 10000 cells were individually encapsulated into droplets and analysed for their IgM secretion after 2-  
193 and 4-days of *in vitro* culture. Among them up to 12% secreted detectable amount of IgM over the 40  
194 minutes of imaging with less secreting cells in the Sec22b<sup>B-KO</sup> condition as expected. We observed that  
195 *in vitro* generated WT PCs secreted on average 12 IgM/sec at day 2 and 20 IgM/sec at day 4. In contrast,  
196 *Sec22b* deficient PCs secreted on average 2 to 4 times less IgM/sec at day 2 and 4, respectively (Figure  
197 4F). Thus, *Sec22b* deficiency leads to a significant reduction, albeit not a total block, in antibody  
198 secretion and to a dramatic reduction of PC survival and proliferation.


199

200 *Sec22b* deficiency profoundly alters the PC transcriptome:

201 To gain further insight into the molecular mechanisms under the control of Sec22b we performed  
202 RNAseq analysis on *in vitro* generated PCs. We chose an early time point, 2 days after LPS stimulation,  
203 to unravel defective mechanisms before the loss of PCs observed rapidly thereafter. Despite being  
204 numerically normal (Figure 4A-B), *Sec22b* deficient PCs at day 2 post stimulation were transcriptionally  
205 very distinct from their WT counterparts as shown by unsupervised analyses (Figure 5A-B and  
206 Supplementary Tables 1 and 2). Over 6000 genes were differentially regulated between both genotypes  
207 with 3388 genes up-regulated and 3184 genes down-regulated in Sec22b<sup>B-KO</sup> PCs compared to WT PCs  
208 (14026 genes total, fold change >1.2 and q-value < 0.05) (Figure 5C). Gene set enrichment analyses  
209 (GSEA) revealed that several pathways were significantly different between WT and Sec22b<sup>B-KO</sup> PCs.  
210 Pathways pertaining to “Cell cycle/mitosis” but also to “Mitochondria” and “Myc targets” were

211 significantly downregulated in *Sec22b*<sup>B-KO</sup> compared to WT PCs, whereas “UPR”, “ER-Golgi transport”  
 212 and “protein secretion” pathways were upregulated (Figure 5D and Supplementary Figures 4 and 5).

**Figure 5**



**Figure 5: Figure 5: *Sec22b* deficiency profoundly alters the PC transcriptome**

(A-E) RNAseq analysis of *Sec22b*<sup>WT</sup> and *Sec22b*<sup>B-KO</sup> PCs generated *in vitro* at day2 post LPS stimulation.

A) Principal component analysis of the RNAseq data of *Sec22b*<sup>WT</sup> and *Sec22b*<sup>B-KO</sup> PCs. The proportion of variance is indicated for PC1 and PC2. B) Unsupervised clustering of *Sec22b*<sup>WT</sup> and *Sec22b*<sup>B-KO</sup> PCs based on the 500 most differentially expressed genes. C) Volcano-plot showing the differentially expressed genes between *Sec22b*<sup>WT</sup> and *Sec22b*<sup>B-KO</sup> PCs. Genes significantly downregulated and upregulated in *Sec22b*<sup>B-KO</sup> PCs are shown in green and red, respectively (FC>1.2; q value<0.05). D) Normalized Enrichment Scores (NES) of representative gene sets significantly enriched in *Sec22b*<sup>B-KO</sup> vs *Sec22b*<sup>WT</sup> PCs and characteristic of selected cellular pathways. Gene sets significantly downregulated and upregulated in *Sec22b*<sup>B-KO</sup> PCs are shown in green and red, respectively. E) Expression of *Ern1* (encoding Ire1a), *Atf4*, *Atf6*, *Ddit3* (encoding Chop) in fragments per kilobase of exon per million reads mapped (FPKM) determined by RNAseq in *Sec22b*<sup>WT</sup> and *Sec22b*<sup>B-KO</sup> PCs. F) Heatmap showing the relative expression of selected ER stress genes from PCs generated from *Sec22b*<sup>WT</sup> and *Sec22b*<sup>B-KO</sup> splenocytes after 2 days of LPS stimulation, determined by Biomark multiplex qPCRs at steady state. The heatmap were generated using the heatmapmer.ca website, row Z score based on (2<sup>-DCT</sup>) values. N=4 and data are representative of 1 or 2 (F) experiments. The p-values were determined with the two-tailed Mann-Whitney non-parametric test \**p* < 0.05.

213  
 214 These results suggest that *Sec22b* expression is key for the regulation of PC biology and highlight  
 215 several *Sec22b*-dependent pathways. In line with our experimental results (Figure 4D), *Sec22b* seems  
 216 essential for promoting cell cycle possibly via control of the Myc signalling axis. In absence of *Sec22b*,


217 genes involved in ER-Golgi transport and secretion were increased despite the observed reduced  
218 antibody secretion rate. This could correspond to a compensatory mechanism to cope with defective  
219 constitutive secretion. Accordingly, and representing a clear sign of exacerbated ER stress, all three  
220 branches of the UPR (i.e. *Ern1*, *Atf4/Ddit3*, *Perk*, *Atf6*) (Figure 5E-F) were upregulated in *Sec22b*<sup>B-KO</sup>  
221 PCs including the Atf4/Chop pathway normally actively repressed in PCs to protect from ER-stress  
222 induced cell death<sup>4</sup>. Our results suggest that in absence of *Sec22b* this protective mechanism is deficient  
223 leading to Chop-mediated cell death and exit from the cell cycle. Furthermore, our RNAseq data  
224 suggests that *Sec22b* deficiency may contribute to defects in several organelles including the ER and  
225 Golgi apparatus.

226

227 *Sec22b* is essential for ER expansion and structure in PCs:

228 As genes involved in ER-Golgi transport were up-regulated in *Sec22b*<sup>B-KO</sup> (Figure 5D-F) mice while the  
229 secretion was reduced (Figure 4E-F) we explored more precisely how *Sec22b* deficiency may affect  
230 these two organelles. We observed using a permeable cell tracker that the ER expansion normally  
231 observed as PC differentiate was significantly reduced in absence of *Sec22b* (Figure 6A). The structure  
232 of the ER was also altered in *Sec22b*<sup>B-KO</sup> PCs. Whereas the perinuclear envelope was roughly normal,  
233 peripheral ER appeared poorly branched with dilated cisternae filled with IgM (Figure 6B), suggestive  
234 of accumulation of hyper-dilated ER and loss of the parallel rough ER typically seen in WT PCs.  
235 Electron microscopy confirmed that the stacked ER sheets characteristic of PCs were lost in absence of  
236 *Sec22b* with a hyper-dilatation of the ER cisternae and a defective stacking that was even more evident  
237 at day 4 (Figure 6C).

**Figure 6**



**Figure 6: Figure 6: Sec22b is essential for ER expansion and structure in PCs**

A) Flow cytometric quantification of ER-Tracker MFI (geometrical mean) on PCs generated from Sec22b<sup>WT</sup> and Sec22b<sup>B-KO</sup> splenocytes after 2 or 4 days of LPS stimulation. B) Confocal microscopy images of Sec22b<sup>WT</sup> and Sec22b<sup>B-KO</sup> PCs obtained from splenocytes stimulated with LPS for 2 days. Cells were stained with anti-IgM to detect antibodies, anti-calnexin to detect the ER and anti-IRF4 antibodies. Nuclei were counterstained with Hoescht. C) Electron microscopy images of Sec22b<sup>WT</sup> (left) and Sec22b<sup>B-KO</sup> (right) PCs obtained from splenocytes stimulated with LPS for 2 (top) or 4 (bottom) days. Red arrowheads indicate ER sheets. Scale bar = 1mm or 0.5mm. D) Flow cytometric quantification of Golgi painter MFI (geometrical mean) on PCs generated from Sec22b<sup>WT</sup> and Sec22b<sup>B-KO</sup> splenocytes after 2 or 4 days of LPS. E) Confocal microscopy images of Sec22b<sup>WT</sup> and Sec22b<sup>B-KO</sup> PCs obtained from splenocytes stimulated with LPS for 2 days. Cells were stained with anti-IgM, anti-GM130 to detect the Golgi and anti-IRF4 antibodies. Nuclei were counterstained with Hoescht. N=4 of 1 representative experiment out of 3. The p-values were determined with the two-tailed Mann-Whitney non-parametric test \**p* < 0.05.

238

239 This suggests that Sec22b expression is crucial for ER spatial expansion and organisation during PC

240 differentiation. In the conventional constitutive secretion route that antibodies were reported to use,

241 proteins leave the ER through the Endoplasmic Reticulum-Golgi Intermediate Compartment (ERGIC)

242 to reach the Golgi apparatus where their final glycosylation occurs. The Golgi apparatus appeared

243 perturbed in Sec22<sup>B-KO</sup> PCs with enhanced intensity of the permeable tracker Golgi painter at day 4  
244 (Figure 6D) and reduced detection of colocalized IgM and of the Golgi marker GM130 (Figure 6E),  
245 suggestive of a block of antibody trafficking between the ER and the Golgi. Altogether, our results  
246 imply a critical role for Sec22b as a regulator of ER organization, structure and function in PCs with  
247 repercussion on the Golgi apparatus as well.


248

249 *Sec22b deficiency affects PC fitness via altered mitochondrial dynamics:*

250 In addition to protein folding and export, an important function of the ER is the control of organelle  
251 dynamics and in particular of mitochondria. Indeed, ER-mitochondria membrane contact sites are  
252 pivotal for mitochondrial fission and thus function<sup>21</sup>. Through our RNAseq analysis we observed a  
253 downregulation of several genes involved in mitochondrial function and dynamics (Figure 5D and  
254 Supplementary Figure 4) including *Drp1*, *Inf2* and *Spire1* that encode proteins involved in mitochondrial  
255 fission at the ER-mitochondria contact site (Figure 7A). Mitochondrial content and potential were  
256 indeed significantly increased in PCs after 4 days in culture in Sec22b<sup>B-KO</sup> PCs compared to WT PCs  
257 (Figure 7B). Accordingly, we detected more mitochondria, increased total mitochondrial area but with  
258 fewer fragments in Sec22b<sup>B-KO</sup> PCs compared to WT PCs (Figure 7C) suggesting an hyperfused  
259 mitochondrial phenotype in Sec22b<sup>B-KO</sup> PCs (Figure 7D). We wondered whether this defective  
260 mitochondrial conformation may contribute to the PC loss observed both *in vivo* and *in vitro* in absence  
261 of Sec22b. Treatment of WT PCs with M1, a Drp1 antagonist, together with Mdivi, an agonist of  
262 mitochondrial fusion, promoted the generation of a hyperfused mitochondria phenotype comparable to  
263 that of Sec22b<sup>B-KO</sup> PCs (Figure 7E). Moreover, M1+Mdivi-treated WT PCs numbers were significantly  
264 reduced in culture compared to control conditions, confirming that mitochondrial dynamics affect PC  
265 fitness (Figure 7F). In addition to this hyperfused phenotype Sec22b<sup>B-KO</sup> PCs presented several  
266 abnormalities in mitochondrial gene expression (Figure 7G) including genes implicated in the  
267 respiratory chain (*Atp5* family), mitochondrial fission (*Mtfp1* and *Mtfr2*), structure (*Timm* and *Tomm*  
268 families) and metabolite transport (*Slc25* family) (Figure 7G) suggesting a global alteration of  
269 mitochondrial size and function in absence of Sec22b. Altogether, these results suggest that Sec22b  
270 expression regulates mitochondrial dynamics in PCs with important consequences for cell fitness.



**Figure 7**



**Figure 7: Figure 7: Sec22b deficiency affects PC fitness via altered mitochondrial dynamics**

A) Expression of *Dnm1l*, *Inf2* and *Spire1* in FPKM determined by RNAseq in *Sec22b<sup>WT</sup>* and *Sec22b<sup>B-KO</sup>* PCs obtained from splenocytes stimulated with LPS for 2 days.  $n=4$  and data are representative of 1 experiment B) Flow cytometric quantification of Mito-tracker (mitoT) green (left) and mitoT orange (right) MFI (geometrical mean) on PCs generated from *Sec22b<sup>WT</sup>* and *Sec22b<sup>B-KO</sup>* splenocytes after 2 or 4 days of LPS stimulation.  $n=4$  mice in 1 representative experiment out of 3. C-D) Confocal microscopy images of PCs obtained from *Sec22b<sup>WT</sup>* and *Sec22b<sup>B-KO</sup>* splenocytes stimulated with LPS for 4 days. Cells were stained with anti-IgM to detect antibodies, anti-cytochrome c to detect mitochondria, anti-IRF4 antibodies and nuclei were counterstained with Hoescht. Scale bar = 10mm. Representative images (C) and quantification (D) of the mean area (top), mean intensity (mean per z-stack) (middle) and number of fragments (over the full cell volume quantified through 10 z-stacks) (bottom) per cell of the cytochrome c staining in PCs obtained from *Sec22b<sup>WT</sup>* and *Sec22b<sup>B-KO</sup>* splenocytes stimulated with LPS for 4 days.  $n=304$  for the WT and  $n=231$  for the *Sec22b<sup>B-KO</sup>* from 3 independent mice per genotype. E-F) 3D projection of confocal microscopy images of PCs obtained from *Sec22b<sup>WT</sup>* and *Sec22b<sup>B-KO</sup>* splenocytes stimulated with LPS for 4 days and after 2 days of treatment with DMSO or M1/Mdivi for *Sec22b<sup>WT</sup>*. Cells were stained with anti-IgM, anti-cytochrome c antibodies and nuclei were counterstained with Hoescht. Scale bar = 6mm. Representative images (E) and quantification (F) of fold change of PC frequency normalized to control *Sec22b<sup>WT</sup>* PCs are shown.  $n=10$  from 2 pooled experiments. G) Supervised heatmap based on RNaseq expression data of 9 mitochondrial gene families differentially expressed between *Sec22b<sup>WT</sup>* and *Sec22b<sup>B-KO</sup>* PCs. For flow cytometry experiment cells were gated on their size and structure, on their viability and doublets were excluded. The p-values were determined with the two-tailed unpaired Mann-Whitney non-parametric test  $*p < 0.05$ ;  $****p < 0.0001$ , "ns" = non-significant p-value.

271

272

## 273 **Discussion**

274 Despite their essential role in health and disease, how PCs maintain a high rate of antibody secretion  
275 and survive this massive protein synthesis and processing burden is unclear. Here we demonstrate that  
276 SNAREs, and in particular Sec22b, are essential for these processes. Indeed, in absence of *Sec22b*  
277 expression in the B cell lineage, the humoral immune response is severely impaired due to decrease in  
278 antibody secretion and defective PC maintenance.

279 The reduced antibody secretion rate observed is likely caused by a defective ER to Golgi transport due  
280 to altered formation of the Stx5/Sec22b SNARE complex. Indeed, fewer IgM were detected in the Golgi  
281 apparatus in absence of Sec22b while large aggregates were observed in the dilated ER. Supporting a  
282 role for this complex in this process, PC treatment with Retro-2, a drug known to block Stx5 canonical  
283 function<sup>19</sup>, also leads to decreased antibody secretion. Interestingly, after Retro-2 treatment but also in  
284 absence of Sec22b, antibody secretion was reduced but not totally abrogated suggesting that redundant  
285 mechanisms may exist to export antibodies via the classical constitutive or via unconventional secretion  
286 pathways<sup>22,23</sup>.

287 The altered PC maintenance in absence of Sec22b cannot uniquely be linked to the defective secretory  
288 capacity of the cells as several studies report that PC survival and antibody secretion can be uncoupled.  
289 For example, mice lacking Xbp1 or the ligase Rctb, important for Xbp1 activation, display reduced  
290 antibody secretion but normal PC numbers<sup>24-27</sup>. Moreover, PC producing pathogenic antibodies often  
291 fail to secrete them while the PC compartment is normal in these mice<sup>28</sup>. Moreover PCs generated in the  
292 LMP2A model can survive without secreting any antibody demonstrating the independence between  
293 antibody secretion and PC survival<sup>29</sup>. Additive defects must thus explain the poor persistence of PCs in  
294 absence of *sec22b*. Importantly, we report here that *Sec22b* deficiency is associated with deregulation  
295 of the UPR as well as morphological alterations of the ER and mitochondria.

296 In PCs, the Ire1 $\alpha$ /Xbp1 axis is normally highly expressed and favours antibody production and folding  
297 without causing cell death<sup>2,30</sup> whereas Atf6 is weakly expressed and the Perk-dependent branch of the  
298 UPR is repressed<sup>4,31</sup>. Activation of the Perk/Atf4/Chop pathway has been associated with increased  
299 susceptibility to cell death in PCs and is normally suppressed by the Ire1 $\alpha$ /Xbp1-dependent Ufbp1  
300 protein<sup>32</sup>. In absence of Sec22b the up-regulation of the three UPR branches may have several

301 consequences. The upregulation of Ire1 $\alpha$  may contribute to compensatory mechanisms to deal with the  
302 decreased ER to Golgi protein transport and for sustaining sub-optimal antibody secretion. In parallel,  
303 the upregulation of Perk may lead to the inhibition of the cell cycle we observed<sup>33</sup> and eventually to PC  
304 cell death<sup>34</sup> hence explaining, in part, the poor PC maintenance *in vitro* and *in vivo* in absence of Sec22b.  
305 Another important observation made in absence of Sec22b was the disturbed ER structure with poorly  
306 stacked and hyper-dilated cisternae that contain antibody aggregates. This could be the consequence of  
307 the reduced transport of antibodies from the ER to the Golgi apparatus but could also be caused directly  
308 by the absence of Sec22b as was shown in yeast and drosophila<sup>35-37</sup>. In yeast, Sec22p interacts with  
309 Sey1p to regulate sterol biosynthesis and with atlastins to support ER homotypic fusion<sup>35,36</sup>. In the  
310 drosophila, Sec22 was identified as an important regulator of ER structure with a profound expansion  
311 of the ER when Sec22 was mutated or knocked-down<sup>37</sup>. More recently, Sec22b knock-down in HUVECs  
312 was also associated with dilated ER but the mechanism at play remain unclear<sup>38</sup>. Interestingly, the long  
313 form of Stx5 was also shown to be important for ER branching via interaction with Climp63 that links  
314 the ER membrane to the microtubules<sup>14</sup>. Thus, Sec22b could directly control ER morphology in PCs  
315 either by interacting with the long form of Stx5 or via another partner still to identify.

316 Another striking defect observed in *Sec22b* deficient PCs was the accumulation of hyperfused  
317 mitochondria. As previously shown in other cell types this could be a consequence of the pronounced  
318 cell cycle exit, as observed herein in Sec22b<sup>B-KO</sup> PCs. Indeed, the kinase CDK1 that is strongly  
319 downregulated in absence of Sec22b phosphorylates Drp1 to promote its recruitment to mitochondria  
320 and the induction of mitochondrial fission<sup>39</sup>. Alternatively, the disrupted structure of the ER in absence  
321 of Sec22b may alter ER/mitochondria contact sites that regulate mitochondrial fission<sup>21</sup>. Sec22b,  
322 through its longin domain, has already been shown to be important for ER/plasma membrane contact  
323 sites and consequently for plasma membrane expansion in neurites<sup>15,40</sup>. Whether Sec22b also contributes  
324 to ER/mitochondria contact sites directly or indirectly remains to be established. In addition, we  
325 demonstrated that hyperfused mitochondria were associated with poor PC survival hence suggesting  
326 that altered mitochondrial dynamics contribute to the decreased PC number in absence of Sec22b.

327

328 To conclude, we demonstrated that Sec22b is a crucial regulator of antibody secretion by regulating  
329 transport between the ER and the Golgi apparatus, a key bottleneck in this process. Moreover, through  
330 regulation of the UPR pathways and ER/mitochondrial dynamics, Sec22b is paramount for PC survival.  
331 Altogether, our results thus demonstrate that Sec22b-mediated regulation of organelle dynamics is  
332 indispensable for PC biology and for the establishment of a protective humoral immune response. They  
333 also open new avenues for targeting PC in pathological contexts.

334

335

336

337

338 **Acknowledgments**

339 We thank Dr. N. Setterblad, C. Doliger and S. Duchez (Plateforme technologique IRSL, Paris, France)  
340 and Dr. V. Parietti (Mouse facility IRSL, Paris, France) for their technical assistance. The study was  
341 supported by the Laboratory of Excellence in Research on Medication and Innovative Therapeutics  
342 (LabEx LERMIT) (ME and KB), an ANR JCJC grant (ANR-19-CE15-0019-01), an ANR @RAction  
343 grant (ANR-14-ACHN-0008), a “Fondation ARC pour la recherche sur le cancer” grant (P  
344 JA20181208173) and a grant from IdEx Université de Paris (ANR-18-IDEX-0001) to ME, an ANR  
345 PRC grant (ANR-17-CE14-0019) and an INCa grant (PRT-K 2017) to KB. P.B. acknowledges funding  
346 from the French National Research Agency grant ANR-18-CE15-0001 project Autoimmuni-B, by the  
347 Institut Carnot Pasteur Microbes et Santé grant ANR-11-CARN-0017-01, the Institut Pasteur and the  
348 Institut National de la Santé et de la Recherche Médicale (INSERM). M.A.L is supported by  
349 Biotechnology and Biological Sciences Research Council (BBS/E/B/000C0427, BBS/E/B/000C0428,  
350 and the Campus Capability Core Grant to the Babraham Institute). AP and MC were supported from a  
351 grant from the Biotechnology and Biological Sciences Research Council (BB/L022389/1). DLH is  
352 supported by a National Health and Medical Research Council Australia Early-Career Fellowship  
353 (APP1139911). NA was supported by a PhD fellowship from the French Ministry for education and by  
354 a 4<sup>th</sup> year PhD fellowship from the “Fondation ARC pour la recherche sur le cancer”. P.C-H. was  
355 supported partly by a stipend from the Pasteur - Paris University (PPU) International PhD program, and  
356 by a fellowship from the French *Fondation pour la Recherche Médicale* (FRM). The "EMiLy" U1160  
357 INSERM unit is a member of the OPALE Carnot institute, The Organization for Partnerships in  
358 Leukemia (Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, Paris,  
359 France. Web : [www.opale.org](http://www.opale.org). Email : [contact@opale.org](mailto:contact@opale.org)).

360

361

362 **Author Contributions**

363 AB designed and performed experiments, analyzed data, and wrote the manuscript. LG, SMG, ER, PCH,  
364 DS, DLH, NR, MC and MAL performed experiments and analyzed data. NA helped with experiments.  
365 SB and VS performed electron microscopy experiments. AA, DG, JB, PB and SA provided essential  
366 reagents and technologies. KGCS and FB contributed to the project design. KB, MAL and AAP  
367 contributed to the project design and to the manuscript redaction. ME designed the project, analyzed  
368 data, and wrote the manuscript. All authors had the opportunity to review and edit the manuscript.

369

370

371 **Declaration of Interests**

372 The authors declare that no conflict of interest exists.

373

374

375 **Methods**

376 *Mouse model, immunisation, and infection*

377 The Sec22b<sup>fl/fl</sup> mice (C57Bl/6J background) were obtained from Dr. Sebastian Amigorena and crossed  
378 with the mb1-Cre mice (C57Bl/6J background) purchased from The Jackson Laboratory. All  
379 experiments were conducted in compliance with the European Union guide for the care and use of  
380 laboratory animals and has been reviewed and approved by appropriate institutional review committees  
381 (C2EA-26, Animal Care and Use Committee, Villejuif, France and Comité d'éthique Paris-Nord N°121,  
382 Paris, France). Immunizations/infections were performed intraperitoneally (ip) with 100µg of 4-  
383 hydroxy-3-nitrophenylacetyl-keyhole limpet hemocyanine (NP-KLH) (Biosearch Technologies)  
384 adjuvanted with alum (Inject Alum, Thermo Scientific) or with 200µL of Sheep Red Blood Cells  
385 (SRBC) (Eurobio) or intranasally with 10<sup>4</sup> plaque-forming units of influenza A/HK/x31 virus (H3N2)  
386 under inhalation anaesthesia with isoflurane. Influenza infections were performed on chimeric mice.  
387 CD45.1 Recipient mice were lethally irradiated with 11gy before reconstitution with bone marrow cells  
388 from Sec22b<sup>B-KO</sup> or Sec22b<sup>B-WT</sup> mice. Chimera were infected 8 to 12 weeks later once reconstitution  
389 was complete.

390

391 *Cell preparation and flow cytometry*

392 Spleen and bone marrow cells were isolated as previously described<sup>41,42</sup>. Briefly, single cell suspensions  
393 were stained with appropriate antibodies (Supplementary table 3) in PBS supplemented with 2%BSA  
394 and 2mM EDTA for cell surface staining. Staining with ERtracker (Invitrogen), mitoTracker Green  
395 (Invitrogen) and mitoTracker Orange (Invitrogen) were performed as recommended by the supplier.  
396 Intracellular staining was performed using the FoxP3/Transcription factor staining buffer set  
397 (eBioscience) according to the provider recommendation. Flow cytometry analyses were performed on  
398 a BD LSR Fortessa cytometer and cell sorting experiments for RNAseq and Biomark analysis were  
399 performed using a BD FACS AriaIII cell sorter. Data were analysed with the Flowjo software (TreeStar,  
400 Ashland, OR).

401

402 *In vitro cell differentiation and infection of primary cells*

403  $1 \times 10^6$  splenocytes were stimulated with  $5 \mu\text{g}/\text{mL}$  of lipopolysaccharide (LPS) (InVivoGen) for 2 or 4  
404 days in complete culture medium composed of RPMI supplemented with 10% foetal calf serum (Sigma),  
405  $0.05 \text{mM}$  2-mercaptoethanol,  $100 \text{U}/\text{mL}$  penicillin-streptomycin,  $1 \text{mM}$  sodium pyruvate and  $0.1 \text{mM}$  non-  
406 essential amino acids (Gibco). Where indicated, cells were treated with  $20 \mu\text{M}$  M1 and  $10 \mu\text{M}$  Mdivi  
407 (Sigma) for 2 days from day 2 to day 4.

408 *Stx5a* specific shRNAs were designed thanks to the RNAi consortium  
409 (<https://portals.broadinstitute.org/gpp/public>) and cloned in the pLKO.3G (addgene #14748) vectors.  
410 Lentiviral particles were produced in the Human Embryonic Kidney 293T (HEK293T) cell line with the  
411 psPAX2 (Addgene #12260) and pMD2.G (Addgene #12259) vectors. For primary cell transduction,  
412 splenocytes were put in culture in complete culture medium in presence of  $80 \text{ng}/\text{ml}$  CD40L  
413 (Thermoscientific) and  $1 \text{U}/\text{mL}$  IL-4 (Miltenyi) for 24 hours to promote B cell entry into cycle. The cells  
414 were then washed and transduced with lentiviral particles together with polybrene. After 24hours cells  
415 were washed and differentiated into PCs by addition of LPS as indicated above.

416

#### 417 *Western blot*

418 Cells were resuspended in RIPA lysis buffer supplemented with Protease and Phosphatase Inhibitor  
419 (Thermofisher). Total proteins were quantified with Bradford buffer (Thermofisher).  $15 \mu\text{g}$  of proteins  
420 were separated on a NuPAGE™ 4-12% Bis-Tris Gel (Invitrogen) and transferred to a PVDF membrane.  
421 Primary antibodies (Supplementary Table 3) or  $\beta$ -actin (Cell Signaling) were incubated overnight at  
422  $4^\circ\text{C}$ . Secondary antibodies (Supplementary Table 3), specific for the primary antibody species,  
423 conjugated to horseradish peroxidase (HRP) were incubated 2h at room temperature and detected using  
424 Pierce ECL (Thermofisher) and signal was quantified by ChemiDoc™ Touch Gel Imaging System (BIO  
425 RAD).

426

#### 427 *Confocal microscopy*

428 Cells were loaded on poly-Lysine (Sigma) coated slides and fixed in PBS/4% PFA prior to analysis.  
429 Cells were permeabilized with PBS/0.3% Triton, washed in PBS and incubated with primary antibodies  
430 coupled or not overnight at  $4^\circ\text{C}$  and then with secondary antibodies 1 hour at room temperature, when



431 necessary (Supplementary Table 3). Cells were incubated with Hoescht (Thermofisher) for 1 hour at  
432 room temperature. Images were acquired using a LSM800 confocal microscope equipped with the  
433 Airyscan system (Zeiss) using a 63x objective and z-stacks. Images were analysed with Fiji and Zen.

434

#### 435 *Electron microscopy*

436 Cells were pre-fixed with 2% glutaraldehyde/2% PFA in Sorensen phosphate buffer 0.1M pH7.2 for 15  
437 minutes before being fixed with 2.5% glutaraldehyde/2% PFA in Sorensen phosphate buffer 0.1M  
438 pH7.2 for 2 hours at room temperature. Cells were then washed in Sorensen phosphate buffer,  
439 resuspended in PFA 1% and sent to the METi platform (Toulouse, France). Cells were then post-fixed  
440 with 1% OsO<sub>4</sub> in Cacodylate buffer (0.1 M, pH 7.2, EMS, Hatfield, PA), rinsed in the same buffer and  
441 pelleted, concentrated in agarose, and treated for 1 h with 2% aqueous uranyl acetate. The samples were  
442 then dehydrated in a graded ethanol series and embedded in Epon. After 48 h of polymerization at 60 °C,  
443 ultrathin sections (80 nm thick) were mounted on 200 mesh Formvar-carbon-coated copper grids.  
444 Finally, sections were stained with Uranylless and lead citrate. Grids were examined with a TEM (Jeol  
445 JEM-1400, JEOL Inc, Peabody, MA, USA) at 80 kV. Images were acquired using a digital camera  
446 (Gatan Orius, Gatan Inc, Pleasanton, CA, USA).

447

#### 448 *ELISA*

449 ELISA assays were performed as previously described<sup>43</sup> for the determination of the different isotype  
450 of Ig or NP-specific antibody titres in sera or culture supernatants. Briefly, plates were pre-coated with  
451 goat anti-mouse IgM (Southern Biotech) or with NP(15)-BSA (Biosearch Technologies). After a step  
452 of saturation in PBS/2%BSA, diluted sera/supernatant were added before incubation with HRP-  
453 conjugated secondary antibody. Enzymatic revelation was performed with the TMB substrate reagent  
454 set (BD OptEIA). All Antibodies used are indicated in Supplementary table 3.

455

#### 456 *Hemagglutination inhibition (HAI) assay*

457 Antibody titers pre and post vaccination were determined using the hemagglutination inhibition (HAI)  
458 assay using the standard WHO protocol, as previously described<sup>44</sup>. Sera were treated overnight with

459 receptor-destroying enzyme (Denka Seiken Co.) and were subsequently tested by standard methods  
460 using 4 HA units of virus and a 0.5% suspension of turkey red blood cells. HAI titers were recorded as  
461 the reciprocal of the highest dilution of the serum that completely inhibited agglutination of erythrocytes  
462 by 4 HA units of the virus.

463

#### 464 *Biomark-based transcriptomic analysis*

465 Multiplex qPCR analysis was performed using the Biomark system (Fluidigm). Cells were sorted at 100  
466 cells/well directly into PCR tubes containing 5 $\mu$ L of reverse transcription/pre-amplification mix as  
467 previously described<sup>41</sup>. Briefly, the mix contained 2X Reaction mix and SuperscriptIII (CellDirect One-  
468 Step qRT-PCR kit, Invitrogen) and 0,2X Taqman assay (Life technologies) (Supplementary Table 4).  
469 Targeted cDNA pre-amplification was performed for 19 cycles before processing with Dynamic Array  
470 protocol according to the manufacturer's instructions (Fluidigm). Wells positive for *Gapdh*, *Actb* and  
471 control gene (*Prdm1*, *Irf4* and *Xpb1* for PCs and *Pax5* for B cells) expression and negative for expression  
472 of a control gene (*Cd3e*) were considered for further analysis. Mean expression of *Actb* and *Gapdh* was  
473 used for normalization. Unsupervised clustering (Spearman rank correlation test) and heatmap  
474 representation were generated with (<http://www.heatmapper.ca>) using the Z scores.

475

#### 476 *RNAseq and RNAseq-based transcriptomic analysis*

477 For RNAseq, *in vitro* generated PCs were sorted at day 2 and RNA were extracted with "RNeasy plus  
478 micro kit" (Qiagen) as recommended. RNAs were proceeded by the Integragen company for sequencing.  
479 Libraries were prepared with NEBNext® Ultra™ II Directional RNA Library Prep Kit for Illumina  
480 protocol according supplier recommendations. Briefly the key stages of this protocol were successively,  
481 the purification of PolyA containing mRNA molecules using poly-T oligo attached magnetic beads from  
482 100ng total RNA (with the Magnetic mRNA Isolation Kit from NEB), a fragmentation using divalent  
483 cations under elevated temperature to obtain approximately 300bp pieces, double strand cDNA  
484 synthesis and finally Illumina adapters ligation and cDNA library amplification by PCR for sequencing.  
485 Sequencing was then carried out on Paired End 100b reads of Illumina NovaSeq. Image analysis and  
486 base calling was performed using Illumina Real Time Analysis (3.4.4) with default parameters.

487 For analysis STAR was used to obtain the number of reads associated to each gene in the Gencode vM24  
488 annotation (restricted to protein-coding genes, antisense and lincRNAs). Raw counts for each sample  
489 were imported into R statistical software. Extracted count matrix was normalized for library size and  
490 coding length of genes to compute FPKM expression levels. The Bioconductor edgeR package was used  
491 to import raw counts into R statistical software, and compute normalized log<sub>2</sub> CPM (counts per millions  
492 of mapped reads) using the TMM (weighted trimmed mean of M-values) as normalization procedure.  
493 The normalized expression matrix from the 500 most variant genes (based on standard deviation) was  
494 used to classify the samples according to their gene expression patterns using principal component  
495 analysis (PCA), hierarchical clustering and consensus clustering. PCA was performed by  
496 FactoMineR::PCA function with “ncp = 10, scale.unit = FALSE” parameters. Hierarchical clustering  
497 was performed by stats::hclust function (with euclidean distance and ward.D method). Differential  
498 expression analysis was performed using the Bioconductor limma package and the voom  
499 transformation. To improve the statistical power of the analysis, only genes expressed in at least one  
500 sample (FPKM >= 0.1) were considered. A q value threshold of <= 0.05 and a minimum fold change of  
501 1.2 were used to define differentially expressed genes. Gene list from the differential analysis was  
502 ordered by decreasing log<sub>2</sub> fold change. Gene set enrichment analysis was performed by  
503 clusterProfiler::GSEA function using the fgsea algorithm. Gene sets from MSigDB v7.2 database were  
504 selected among the C2\_curated and Hallmark classes, keeping only gene sets defined by 10-500 genes.

505

#### 506 *DropMap-based analysis of IgM secretion*

507 Dropmap experiment were performed as described<sup>1</sup>, modified to detect IgM secretion from single cell.  
508 Cells from *in vitro* cultures at day2 or day 4 after LPS stimulation were centrifuged and resuspended in  
509 DropMap medium (RPMI without phenol red, supplemented with 0.1% Pluronic F68, 25 mM HEPES  
510 pH 7.4, 10% KO serum replacement (all ThermoFisher) and 0.5% recombinant human serum albumin  
511 (Sigma Aldrich). Microfluidic droplets were generated as water-in-oil emulsions using a co-flow of  
512 aqueous phases, one containing bioassay reagents (bioassay phase) and the other one containing *in vitro*-  
513 generated PCs (cell phase). *Bioassay phase*: Streptavidin-coated paramagnetic beads (300nm,  
514 Ademtech) were washed with PBS using a magnet, and then resuspended in a 1μM solution of

515 CaptureSelect biotin anti-mouse Igk conjugate (ThermoFisher) and incubated at room temperature (RT)  
516 for 20 min. The beads were washed with PBS and resuspended in 5% pluronic F127 (ThermoFisher)  
517 and incubated for 20 min at room temperature. Following a PBS wash, the beads were resuspended in  
518 DropMap buffer and incubated at RT for 20 min. Beads were washed for the last time with PBS and  
519 resuspended in a solution of 150nM Goat anti-mouse IgM ( $\mu$  chain specific) F(ab')<sub>2</sub> (Alexa647, Jackson  
520 ImmunoResearch) in DropMap buffer. *Cell phase*: To produce single-cell droplets, cell concentration  
521 was adjusted to achieve 0.3 cells per droplet in DropMap buffer. For calibration purposes with cells,  
522 purified monoclonal IgM was diluted in DropMap buffer.

523 Droplets were produced by hydrodynamic flow-focusing on a custom-made microfluidic device as in<sup>1</sup>,  
524 by co-flowing the two aqueous phases. Immediately after generation, droplets were injected into the 2D  
525 observation chamber<sup>1</sup> until filled, which was then closed for image acquisition. The droplet array in the  
526 2D chamber was imaged using a Nikon Ti-2 Eclipse inverted microscope with motorized stage and  
527 excitation light source (Lumencor Spectra X). Fluorescence was captured using a 10x objective and a  
528 Cy5 filter, and images were recorded by a digital CMOS camera (ORCA-flash 4.0, Hamamatsu). For  
529 each time point, an array of 10x10 images was acquired, and a total of 6 acquisitions were recorded  
530 through 37.5 min. The images were analyzed with a custom Matlab script as described<sup>1</sup>. In brief, the  
531 ratio of fluorescent signal between the beadline and the background was estimated for every droplet at  
532 every time point. The fluorescence ratio was then used to estimate the concentration of IgM in the  
533 droplets by using a calibration curve, which was generated by measuring the fluorescent ratio from  
534 different concentrations of purified monoclonal IgM antibody.

535

### 536 *Statistical analysis*

537 The p-values were determined as indicated in the figure legends using the Prism GraphPad software  
538 with the two-tailed unpaired Mann-Whitney non-parametric test for the WT vs Sec22b<sup>B-KO</sup> comparison  
539 ( $*p < 0.05$ ;  $**p < 0.01$ ;  $***p < 0.001$ ;  $****p < 0.0001$ , “ns” = non-significant  $p$ -value), or with the 2way  
540 ANOVA with Sidak correction for multiple comparisons (**ff**  $p < 0.01$ , **fff**  $p < 0.001$ ).

541

542 **Supplemental Information titles and legends**

543 **Supplementary figure 1: Raw Label-Free Quantification intensity values for the indicated**  
544 **proteins measured by LC-MS/MS analysis**

545 **Supplementary figure 2: Stx5 controls plasma cell maintenance and antibody secretion**

546 **Supplementary figure 3: Characterization of the *Sec22b*<sup>B-KO</sup> mouse model**

547 **Supplementary figure 4: Under-represented gene sets in *Sec22b*<sup>B-KO</sup> PCs**

548 **Supplementary figure 5: Over-represented gene sets in *Sec22b*<sup>B-KO</sup> PCs**

549

550 **Supplementary Table 1: 250 top down regulated genes in *Sec22b*<sup>B-KO</sup> PCs**

551 **Supplementary table 2: 250 top up regulated genes in *Sec22b*<sup>B-KO</sup> PCs**

552 **Supplementary table 3: List of antibodies used in flow cytometry, western blot and**  
553 **immunofluorescence**

554 **Supplementary table 4: List of primers used for Biomark based qPCR**

555

556 **References**

- 557 1. Eyer, K. *et al.* Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune  
558 monitoring. *Nat. Biotechnol.* **35**, 977–982 (2017).
- 559 2. Iwakoshi, N. N. *et al.* Plasma cell differentiation and the unfolded protein response intersect at the  
560 transcription factor XBP-1. *Nat Immunol* **4**, 321–329 (2003).
- 561 3. Kirk, S. J., Cliff, J. M., Thomas, J. A. & Ward, T. H. Biogenesis of secretory organelles during B  
562 cell differentiation. *J Leukoc Biol* **87**, 245–255 (2010).
- 563 4. Ma, Y., Shimizu, Y., Mann, M. J., Jin, Y. & Hendershot, L. M. Plasma cell differentiation  
564 initiates a limited ER stress response by specifically suppressing the PERK-dependent branch of  
565 the unfolded protein response. *Cell Stress and Chaperones* **15**, 281–293 (2010).
- 566 5. Melchers, F. Biosynthesis, transport and secretion of immunoglobulin in plasma cells. *Histochem.*  
567 *J.* **3**, 389–397 (1971).
- 568 6. Reales, E. *et al.* Identification of Soluble *N*-Ethylmaleimide-Sensitive Factor Attachment Protein  
569 Receptor Exocytotic Machinery in Human Plasma Cells: SNAP-23 Is Essential for Antibody  
570 Secretion. *J Immunol* **175**, 6686–6693 (2005).
- 571 7. Tartakoff, A., Vassali, P. & Detraz, M. Plasma cell immunoglobulin secretion. Arrest is  
572 accompanied by alterations the golgi complex. *Journal of Experimental Medicine* **146**, 1332–1345  
573 (1977).
- 574 8. Cortini, M. & Sitia, R. From antibodies to adiponectin: role of ERp44 in sizing and timing protein  
575 secretion. *Diabetes Obes Metab* **12 Suppl 2**, 39–47 (2010).
- 576 9. Jahn, R. & Scheller, R. H. SNAREs--engines for membrane fusion. *Nat Rev Mol Cell Biol* **7**, 631–  
577 643 (2006).
- 578 10. Gordon, D. E., Bond, L. M., Sahlender, D. A. & Peden, A. A. A targeted siRNA screen to identify  
579 SNAREs required for constitutive secretion in mammalian cells. *Traffic* **11**, 1191–1204 (2010).
- 580 11. Alloatti, A. *et al.* Critical role for Sec22b-dependent antigen cross-presentation in antitumor  
581 immunity. *J. Exp. Med.* **214**, 2231–2241 (2017).
- 582 12. Cebrian, I. *et al.* Sec22b regulates phagosomal maturation and antigen crosspresentation by  
583 dendritic cells. *Cell* **147**, 1355–1368 (2011).

- 584 13. Kimura, T. *et al.* Dedicated SNAREs and specialized TRIM cargo receptors mediate secretory  
585 autophagy. *EMBO J* **36**, 42–60 (2017).
- 586 14. Miyazaki, K. *et al.* Contribution of the long form of syntaxin 5 to the organization of the  
587 endoplasmic reticulum. *J Cell Sci* **125**, 5658–5666 (2012).
- 588 15. Petkovic, M. *et al.* The SNARE Sec22b has a non-fusogenic function in plasma membrane  
589 expansion. *Nat Cell Biol* **16**, 434–444 (2014).
- 590 16. Renna, M. *et al.* Autophagic substrate clearance requires activity of the syntaxin-5 SNARE  
591 complex. *J Cell Sci* **124**, 469–482 (2011).
- 592 17. Gonzalez, L. C., Weis, W. I. & Scheller, R. H. A novel snare N-terminal domain revealed by the  
593 crystal structure of Sec22b. *J Biol Chem* **276**, 24203–24211 (2001).
- 594 18. Hay, J. C., Chao, D. S., Kuo, C. S. & Scheller, R. H. Protein interactions regulating vesicle  
595 transport between the endoplasmic reticulum and Golgi apparatus in mammalian cells. *Cell* **89**,  
596 149–158 (1997).
- 597 19. Forrester, A. *et al.* Functional dissection of the retrograde Shiga toxin trafficking inhibitor Retro-  
598 2. *Nat Chem Biol* **16**, 327–336 (2020).
- 599 20. Stechmann, B. *et al.* Inhibition of Retrograde Transport Protects Mice from Lethal Ricin  
600 Challenge. *Cell* **141**, 231–242 (2010).
- 601 21. Giacomello, M., Pyakurel, A., Glytsou, C. & Scorrano, L. The cell biology of mitochondrial  
602 membrane dynamics. *Nat Rev Mol Cell Biol* **21**, 204–224 (2020).
- 603 22. Gordon, D. E. *et al.* VAMP3/Syb and YKT6 are required for the fusion of constitutive secretory  
604 carriers with the plasma membrane. *PLoS Genet* **13**, e1006698 (2017).
- 605 23. Liu, Y. & Barlowe, C. Analysis of Sec22p in endoplasmic reticulum/Golgi transport reveals  
606 cellular redundancy in SNARE protein function. *Mol Biol Cell* **13**, 3314–3324 (2002).
- 607 24. Jurkin, J. *et al.* The mammalian tRNA ligase complex mediates splicing of XBP1 mRNA and  
608 controls antibody secretion in plasma cells. *EMBO J* **33**, 2922–2936 (2014).
- 609 25. McGehee, A. M. *et al.* XBP-1-Deficient Plasmablasts Show Normal Protein Folding but Altered  
610 Glycosylation and Lipid Synthesis. *The Journal of Immunology* **183**, 3690–3699 (2009).

- 611 26. Reimold, A. M. *et al.* Plasma cell differentiation requires the transcription factor XBP-1. *Nature*  
612 **412**, 300–307 (2001).
- 613 27. Taubenheim, N. *et al.* High rate of antibody secretion is not integral to plasma cell differentiation  
614 as revealed by XBP-1 deficiency. *J. Immunol.* **189**, 3328–3338 (2012).
- 615 28. Bonaud, A. *et al.* A mouse model recapitulating human monoclonal heavy chain deposition  
616 disease evidences the relevance of proteasome inhibitor therapy. *Blood* **126**, 757–765 (2015).
- 617 29. Casola, S. *et al.* B cell receptor signal strength determines B cell fate. *Nat. Immunol.* **5**, 317–327  
618 (2004).
- 619 30. Tellier, J. *et al.* Blimp-1 controls plasma cell function through the regulation of immunoglobulin  
620 secretion and the unfolded protein response. *Nat Immunol* **17**, 323–330 (2016).
- 621 31. Gaudette, B. T., Iwakoshi, N. N. & Boise, L. H. Bcl-xL protein protects from C/EBP homologous  
622 protein (CHOP)-dependent apoptosis during plasma cell differentiation. *J Biol Chem* **289**, 23629–  
623 23640 (2014).
- 624 32. Zhu, H. *et al.* Ufbp1 promotes plasma cell development and ER expansion by modulating distinct  
625 branches of UPR. *Nat Commun* **10**, 1084 (2019).
- 626 33. Brewer, J. W. & Diehl, J. A. PERK mediates cell-cycle exit during the mammalian unfolded  
627 protein response. *Proc Natl Acad Sci U S A* **97**, 12625–12630 (2000).
- 628 34. Bustany, S., Cahu, J., Guardiola, P. & Sola, B. Cyclin D1 sensitizes myeloma cells to  
629 endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response  
630 pathway. *BMC Cancer* **15**, 262 (2015).
- 631 35. Lee, M. *et al.* SNAREs support atlastin-mediated homotypic ER fusion in *Saccharomyces*  
632 *cerevisiae*. *J Cell Biol* **210**, 451–470 (2015).
- 633 36. Lee, M., Moon, Y., Lee, S., Lee, C. & Jun, Y. Ergosterol interacts with Sey1p to promote atlastin-  
634 mediated endoplasmic reticulum membrane fusion in *Saccharomyces cerevisiae*. *FASEB J* **33**,  
635 3590–3600 (2019).
- 636 37. Zhao, X. *et al.* Sec22 regulates endoplasmic reticulum morphology but not autophagy and is  
637 required for eye development in *Drosophila*. *J Biol Chem* **290**, 7943–7951 (2015).



- 638 38. Karampini, E. *et al.* Sec22b determines Weibel-Palade body length by controlling anterograde  
639 ER-Golgi transport. *Haematologica* **106**, 1138–1147 (2021).
- 640 39. Taguchi, N., Ishihara, N., Jofuku, A., Oka, T. & Mihara, K. Mitotic phosphorylation of dynamin-  
641 related GTPase Drp1 participates in mitochondrial fission. *J Biol Chem* **282**, 11521–11529  
642 (2007).
- 643 40. Gallo, A. *et al.* Role of the Sec22b-E-Syt complex in neurite growth and ramification. *J Cell Sci*  
644 **133**, jcs247148 (2020).
- 645 41. Alouche, N. *et al.* Hematologic disorder-associated Cxcr4 gain-of-function mutation leads to  
646 uncontrolled extrafollicular immune response. *Blood* **137**, 3050–3063 (2021).
- 647 42. Bonaud, A., Balabanian, K. & Espéli, M. Immunophenotyping of the Medullary B Cell  
648 Compartment In Mouse Models. *Methods Mol Biol* **2308**, 95–105 (2021).
- 649 43. Bonaud, A. *et al.* Leupaxin Expression Is Dispensable for B Cell Immune Responses. *Front.*  
650 *Immunol.* **11**, 466 (2020).
- 651 44. Chen, G. L., Lamirande, E. W., Jin, H., Kemble, G. & Subbarao, K. Safety, immunogenicity, and  
652 efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets. *Virology* **398**,  
653 109–114 (2010).
- 654  
655